Combination drug
A combination drug is a medication consisting of at least two drugs as active ingredients combined in a single dosage form, usually in a fixed-dose combination, where each active component is at an exactified, standardized dose. Fixed-dose combinations are mass produced and mass marketed, intended to serve as a near universal treatment for a large patient population with diverse medical histories, conditions, predisposition thereof, and treatment requirements. A polypill is a pharmacy or capsule containing four or more active ingredients, often needing to be compounded at a specialized pharmacy in order to satisfy a patient's medical prescription (e.g. dosage form, dose, and/or mechanism/action of release ias part of the individual's overall care and personalized treatment plan. Polypills encompass approved prescription drugs, over the counter drugs, as well as nutritional supplements, amino acids, vitamins, minerals, and hormones as necessary.
Fixed-dose combination drugs were initially developed to target a single disease, as with antiretroviral FDCs indicated for treating AIDS and HIV. Over time, the concept of combination drugs has come to include reducing pill burden for patients, thereby encouraging patient compliance, and generally simplifying treatment plan with one product containing easily accessible (often available over the counter without a prescription requirement), relatively affordable (often generic drugs) ingredients with established therapeutic efficacy and a broad capacity for treating a variety of symptoms and conditions, thus ensuring maximum appeal to a majority of patients amongst a large population with varying needs.
Current prescription combination drugs
The combination drugs listed below are typically available by prescription only, but specific circumstances regarding a given combination's legal accessibility, or any specific regulation pertinent to ingredient quality, quantities, production standards, sourcing, etc. will vary by jurisdictions, and include:
- amitriptyline/perphenazine, common brand Triavil
- amlodipine/benazepril common brand Lotrel
- bupropion/naltrexone, common brand Contrave
- Butapap is a common brand name for fixed doses of butalbital, acetaminophen, caffeine and codeine
- amitriptyline/chlordiazepoxide, commonl brand Limbitrol and available OTC in India
- Amlodipine/atorvastatin common brand Conduet
- Amlodipine/celecoxib, common brand Consensai
- amlodipine/olmesartan, common brand Azor
- Amlodipine/valsartan, common brand Exforge
- chlordiazepoxide combined with clidinium bromide
- chlorpheniramine maleate, dextromethorphan hydrobromide, guaifenisin, acetaminophen, and commonly branded Coricidin
- Dimenhydrinate and promethazine.
- ephedrine/ethylmorphine
- Lisinopril/amlodipine
- Lisinopril/hydrochlorothiazide
- nirmatrelvir/ritonavir was granted emergency use authorization by the U.S. Food and Drug Administration for the treatment and management of COVID-19, branded Paxlovid.
- hydrocodone/acetaminophen, common brands Norco and Vicodin
- flupentixol/melitracen, patented Deanxit by Lundbeck, available in India
- hydrocodone/aspirin brand Azdone
- hydrocodone/guaifenesin, brandededObedron
- hydrocodone/ibuprofen, branded Ibudone
- omeprazole/amoxicillin/rifabutin, common brand Talicia
- olanzapine/fluoxetine, branded Symbyax
- oxycodone/acetaminophen, common brand Percocet
- oxycodone/aspirin, commonly Percodan
- oxycodone/ibuprofen, commonly Combunol
- phentermine/topiramate patented as Qsymia
- phenylephrine/ketorolac, brand Omidria]]
- phenylephrine/ketorolac<
- Amphetamine, mixed salts of the racemic single entity amphetamine: dextroamphetamine sulfate, dextroamphetamine saccharate, levoamphetamine aspartate monohydrate, levoamphetaminee sulfate, commonly Adderall and Mydayis
- pseudoephedrine/carbinoxamine, Rondec syruo
Combination drugs accessible Over-the-counter (OTC)
Fixed-dose combination drugs for sale over the counter (OTC) exist around the world, constituting doses that are tolerable to the mainstream consumer population. In the United States, items containing ephedrine, pseudoephedrine, or phenylpropanolamine can be purchased without a prescription, albeit under oversight and at the pharmacy, per U.S. Federal drug law, namely the Combat Methamphetamine Epidemic Act of 2005.
Fixed-dose combination drugs for sale over the counter internationally, including medicine indicated for various purposes:
- Anacin by Bayer, tablet dosage form since 1916: 32mg caffeine and 400mg aspirin
- Allerest, Chlor-Rest, Tri-Nefrin (pill); Altec Syrup (liquid tincture); Vernate (liquid injection) by Tutag Pharmaceuticals: 8mg chlorpheniramine maleate and 50mg PPA per serving.: chlorpheniramine (first-generation antihistamine) and phenylpropanolamine (PPA, a sympathomimetic nasal decongestant)
- Coricidin Cold & Cough by Bayer: fixed-dose combination drug containing dextromethorphan hydrobromide (a cough suppressant), 2mg chlorpheniramine maleate (first-generation antihistamine), and 200mg guaifenesin (expectorant); indicated for cough, cold-like and flu-like symptoms, allergic rhinitis, chest congestion; Coricidin HBP contains an additional 325mg acetaminophen.
- Toplexil combines oxomemazine (sedative antihistamine) and an expectorant, respectively. Never FDA-approved for use in the U.S.
- Dramamine by Merck lists dimenhydrinate as its active ingredient. Dimenhydrinate, however, is a combination 8-chlorotheophylline and diphenhydramine
- glucose/fructose/phosphoric acid] together as the brand name Emetrol for Nausea]]
- Excedrin (product line by Bayer: 250mg aspirin, 400 mg acetaminophen, and 35mg caffeine
- ibuprofen/famotidine brand Duexis combination of an anti-flammatory analgesic, and proton pump inhibitor
- naproxen/diphenhydramine, branded Aleve PM, 220mg naproxen, 12.5mg diphenhydramine hydrochloride, analgesic sleep aid
- ibuprofen/diphenhydramine (AdvilPM]]) 400mg ibuprofen, 25mg diphenhydramine hydrochloride
- Allegra-D, a second-generation antihistamine and a sympathomimetic decongestant
- Claritin-D
- Zyrtec-D, 5mg ceterizine (ZyrTec) and pseudoephedrine hydrochloride (sympathomimetic decongestant)
- Aleve-D: 220mg naproxen (NSAID) and pseudoephedrine (sympathomimetic)
- Robitussin: cough medicines comprising dextromethorphan, acetaminophen, chlorpheniramine,
- Sudafed PE: combinated guaifenesin and phenylephrine (expectorant and nasal decongestant).
- Tylenol PM: 500mg acetaminophen, 38mg diphenhydramine hydrochloride
Combination drugs under development, not yet approved for medical use
- MDMA/citalopram: an empathogen called "Ecstasy" combined with citalopram (SSRI); currently under development in FDA Phase II clinical trials.
Combinations drugs for veterinary use
- Temaril-P: alimemazine and prednisolone; indicated as antitussive and antipruritic in dogs, generic since 2024. The generic alternative to the brand version substitutes alimemazine with trimeprazine, but is otherwise identical in terms of formulation and efficacy.
- Titzeol: combination of tiletamine and zolazepam both major tranquilizers, intended to sedate large animals
Combination drugs no longer widely available
- Acutran: dextroamphetamine sulfate and chloral hydrate), discontinued 1973
- Ambar and Ambar Extentab: methamphetamine hydrochloride and phenobarbital sodium; Ambar Extentab (XR) formulation
- Amvicel by Roehrig: 10mg dextroamphetamine sulfate, 30mg nicotinamide, 40mg amobarbital and 15mg phenobarbital salts, vitamins, minerals
- Anox by Winston Biotech, polypill capsule: 7.5mg methamphetamine hydrochloride, 7.5mg dextroamphetamine, 20mg phenobarbital sodium, 20mg butabarbital, 20mg secobarbital; Diacelx: extended-release formulation launched 1965
- Anxine: 2.5mg dextroamphetamine sulfate, 35mg cyclobarbital, and 120mg mephenesin (a muscle relaxant)
- BamaDex by Behlen: fixed-dose combination of 6mg dextroamphetamine saccharate and meprobamate
- Biphetamine T-12.5by Fisons: 12.5mg racemic amphetamine (1:1 mixture 6.25mg levoamphetamine:6.25mg dextroamphetamine)
- Biphetamine T-20 by Fisons: 20mg racemic amphetamine (10mg levoamphetamine:10mg dextroamphetamine)
- Desbutal: 5mg methamphetamine hydrochloride and 30mg pentobarbital sodium, discontinued 1973
- Dexamyl: dextroamphetamine and amobarbital sodium, discontinued 1982
- Durophet M: 13mg racemic amphetamine (1:1 6.25mg levoamphetamine:6.5mg dextroamphetamine, 40mg methaqualone hydrochloride
- Esbelcaps: 20mg fenproporex and 6mg diazepam, once widely available throughout Central and South American countries
- Eskatrol by Smith, Kline & French Laboratories: brand name of a weight loss medication combining dextroamphetamine and prochlorperazine; discontinued 1981
- Euphoramin: 5mg methamphetamine hydrochloride, 300mg meprobamate
- Phelantin (capsule) by Parke-Davis: 100mg phenytoin (anticonvulsant), 30mg pentobarbital (depressant, antiepileptic), and 2.5mg methamphetamine hydrochloride (mild counteraction of sedation)
- Amplus Now by Pfizer-Roerig Inc.–combined 5mg dextroamphetamine sulfate and 5mg hydroxyzine
- NalerTan and Durabond by Irwin, Neisler and Co. : 10mg Tanphetamin (Neisler-branded dextroamphetamine tannate) combined with 8mg chlorpheniramine tannate, and 25mg pyrilamine tannate
- Obocell by Irwin, Neisler and Co.: 5mg dextroamphetamine phosphate 25mg methapyrilene phosphate; Obocell-TF was the previous formula with the addition of 160mg per tablet of high-viscosity methylcellulose
- SynaTan-S by Irwin, Neisler and Co.: 10mg Tanphetamin (dextroamphetamine tannate) combined with 35mg secobarbital sodium. Mallinckrodt acquired Neisler Laboratories in 1976 and rebranded the product as OboTan-S: formerly SynaTan-S.
- Pre-M-T by Behlen Laboratories, a polypill and tablet containing: levoamphetamine sulfate, dextroamphetamine sulfate, pentobarbital sodium, pyrilamine maleate, and a micro-dose of theobromine.
- Amphaplex 10:2.5mg methamphetamine saccharate, 2.5mg methamphetamine hydrochloride, and 5mg racemic amphetamine sulfate (2.5mg levoamphetamine sulfate:2.5mg dextroamphetamine; and Amphaplex 20– 5mg methamphetamine saccharate, 5mg methamphetamine hydrochloride, and 10mg racemic amphetamine sulfate (5mg levoamphetamine sulfate: 5mg dextroamphetamine sulfate)
- Bontril Timed No. 1: 2.5mg dextroamphetamine and 7.5mg butarbartal; Bontril Timed No. 2: 5mg dextroamphetamine, 15mg butabarbital; Bontril No. 3: 10mg dextroamphetamine, 30mg butabarbital; Bontril Timed No. 4: 15mg dextroamphetamine, 60mg butabarbital
- Delcobese was 4 components of single-entity racemic amphetamine: 1/4 racemic amphetamine (l- and d- isomers) adipate and 1/4 racemic (l- and d- isomers) amphetamine sulfatedextroamphetamine adipate, and dextroamphetamine sulfate.
- Obetrol by Abbott Laboratories was a combination of various mixed salts of methamphetamine and dextroamphetamine salts; discontinued in 1973 following a crackdown by the DEA on combination drugs composed of controlled substances of the DEA and a subsequent crackdown on combination medicines. Obetrol was reformulated as Oby-Rex and replaced the methamphetamine salts with salts from the other half of racemic amphetamine, which is technically a single entity, hence obyRex.hetamine.
- Pondimin ("Fen-Phen") – fenfluramine/phentermine, anti-obesity medication discontinued 1998
- Reladorm – 100mg cyclobarbital and 10mg diazepam, insomnia treatment (soporific) in Russia, discontinued 2019
- Tuinal– Tuinal combined two barbiturate salts, namely sodium amobarbital and secobarbital, discontinued late 1990s
- Mandrax – methaqualone and diphenhydramine, formerly available in South Africa, now limited to clandestine chemistry
- Artogesic: – dextroamphetamine and mephobarbital with phenacetin and salicylamide
- Apamead – dextroamphetamine sulfate and amobarbital with aspirin and phenacetin
- Dysonil – methamphetamine hydrochloride, pentobarbital sodium, and salicylamide)
- Edrisal–160mg aspirin, 160mg phenacetin, and 2.5mg amphetamine sulfate; Edrisal with Codeine was an identical formulation that included the addition of 16mg codeine
- Daprisal by GlaxoSmith Kline – dextroamphetamine sulfate, 32.5mg amobarbital, and 162.5mg aspirin
- Decobese – 15mg dextroamphetamine and 16mg amobarbital, with 75mg betaine anhydrous and 194mg bile salts
- Direcel: dextroamphetamine, butabarbital, and carboxymethylcellulose; Direcel-T was identical with the inclusion of thyroid hormone
- Duodex – capsule containing 16.25 mg aloin, 15mg amphetamine sulfate, 16.25mg pentobarbital, and thyroid hormone
- Elpanal by Teva Pharmaceuticals: 500mg acetaminophen, 15mg amobarbital, and 2.5mg methamphetamine hydrochloride; Lamital by Teva was merely the sustained-release formulation.
- Mediatric – 0.25mg Premarin (Conjugated Estrogens USP), 2.5mg methyltestosterone, 100mg ascorbic acid, B vitamins, and 1mg methamphetamine hydrochloride
- Nexorin: dextroamphetamine sulfate, amobarbital, methylcellulose, and supplements
- Obolip: dextroamphetamine and phenobarbital, with choline bitartrate, di-methionine, and methylcellulose
Medical use and justification of discontinued combination drugs
Most of the combination drugs which have been discontinued since the twentieth century were simultaneously indicated and utilized for treatment of various conditions, with medical use justified as part of a multifaceted, comprehensive approach to patient health care and medical treatment. Central nervous system stimulants (colloquially called "uppers") were used as appetite suppressants, antidepressants, and wakefulness-promoting agents, and further effects include increased mental alertness and concentration/focus, as well as physical energy and motivation. The addition of a central nervous system depressant mitigated the stimulant's adverse effects without eliminating therapeutic benefits. In most cases, the "upper" component of these combination drugs was a salt, or mixed salts, of racemic amphetamine, dextroamphetamine, or methamphetamine, while the "downer" was typically one or more barbiturates (most commonly amobarbital, phenobarbital, pentobarbital, and/or secobarbital) or similar GABAergic, non-barbiturate tranquilizers or sedatives, frequently meprobamate or methaqualone, respectively, which provided anxiolytic, muscle relaxant, and hypnotic effects. Upper and downer combination drugs were often capable of substituting for Monoamine Oxidase Inhibitors (MAOIs) in patients with treatment-resistant depression where MAOIs are indicated, but where MAOI-related dietary restrictions would impact patient's life.
Combination drugs offer the advantage over polypharmacy by decreasing patients' pill burden. Overall, giving patients the ability to take control and alleviate symptoms, and potentially treat or cure multiple conditions by consuming all of their medical treatments efficacious treatment options by the ingestion of a single pill, which consistently improves patient medication compliance by reducing their pill burden. The American Association of Orthodontists asserts that fixed-dose combinations "limit clinicians' ability to customize dosing regimens."
Scientists formulating combination drugs face challenges in the development stages of multi-drug formulations such as compatibility issues among active ingredients and excipients affecting solubility and dissolution For prescribers, if one constituent of the combination is contraindicated for a patient, the product cannot be prescribed.
Illicit streets as de facto drug combinations
Illicit stimulants
Illicit combination drugs are often formulated as a powder, paste, or counterfeit "pressed" pills intended to resemble their pharmaceutical-grade counterparts. Since 2018, ABC News of Houston reports that product described as "powder cocaine" originating from a clandestine laboratory are increasingly analyzed and found to contain other stimulants, in order to mimic cocaine's effects in a cost-effective, deceptive manner; many of the batches analyzed did not contain any cocaine or coca alkaloids whatsoever; instead, they were blends of various designer drugs, research chemicals, methamphetamine, and/or various amphetamines, derivatives, analogues; MDMA, caffeine powder, ephedrine or pseudoephedrine; levamisole, a flesh-eating veterinary antibiotic
Limitations of currently-available combinations
The limitations of combination formulations currently available for treating a widely-inclusive collection of symptoms such as Tourette's is highlighted by there not being a polypill or any combination formula period approved for treating the condition. Medication available, and sometimes used in the context of polypharmacy involves various individual medicines for treating tics and/or generalized anxiety or social anxiety disorder and/or obsessive-compulsive anxieties with use of individual benzodiazepines or SSRIs for the former two conditions, and fluvoxamine or clomipramine first-line treatments for OCD and related disorders, such as hoarding or compulsive decluttering. But, where Attention-Deficit Hyperactivity Disorder, depression, or insomnia become a primary concern to the patient, it is only through polypharmacy (in this case, adding another antidepressant or a "booster, alongside a hypnotic soporific agent, and/or psychostimulants to both treat ADHD and counteract the sleep inertia, grogginess or hangover caused by the other evening medications).
Tourette syndrome is a neurological tic disorder whose only FDA-approved treatment is the neuroleptic pimozide, a drug only used for tics due Tourette's disorder; every other treatment is an off-label use. While Tourette's is typically identified by chronic motor and vocal tics–"semi-voluntary" movements and noises made in response to a "premonitory urge," an internal buildup of compulsive tension that can only be temporarily upon performing/making the motion/sound demanded by compulsion. Tourette's, however, is an all-encompassing umbrella term that includes not just chronic physical and phonic tics, but also presents with such comorbid symptoms as anxiety (often OCD, social anxiety, schizoid personality, avoidant personality disorder, or generalized anxiety), ADHD, insomnia, depression, and traits of high-functioning autism formerly called Asperger syndrome.
Illicit depressants and opiates
Due to the crackdown of pill mills between 2007-2012, the opioid epidemic now includes preparations declared to be "heroin" or "pressed" replica pills of hydrocodone (sold Norco or LorTab); oxycodone (sold as Percocet), yet are rarely pure in their ingredient compositions. Cutting agents have grown in proportion to the overall composition of these products, such that "heroin" has been cut and mixed with central nervous system depressants including major tranquilizers such as quetiapine; muscle relaxants like carisoprodol or cyclobenzaprine; first-generation antihistamines like diphenhydramine or hydroxyzine); and benzodiazepine derivative and analogue research chemicals, including gidazepam, pinazepam, clobromazolam, etizolam). Since 2020, there has been a noticeable rise amongst active ingredients in opioid combinations containing fentanyl (more potent than heroin), and increasingly, carfentanil (an elephant and rhinoceros tranquilizer more potent than fentanyl).
Since 2023, worldwide samples of illicit combinations featuring opioids have contained the most lethal known substance to date: those belong to the nitazene chemical class. have been found in these opioid samples– all of which mimic the muscle relaxant, anxiolytic, and analgesic properties of pharmaceutical-grade opioid medications. U.S. Attorney General has indicated interested in federally regulating the relative mild veterinary sedative xylazine, which is currently available by prescription only, as a federally-controlled Schedule III controlled substance per the Controlled Substances Act, a direct response to its implication in overdose deaths featured in products alongside fentanyl and other power central nervous system depressants; xylazine is currently a controlled substance at the state level in Michigan and New York.
See also
- Codrugs
- Synergy#Drug synergy
- 2016 Revision of the United Nations List of Psychotropic Substances & Nomenclature [this link]
Notes
References
External links
Media related to Combination drugs at Wikimedia Commons